Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Trinity Biotech (TRIB) Common Equity (2016 - 2025)

Historic Common Equity for Trinity Biotech (TRIB) over the last 17 years, with Q2 2025 value amounting to $4.3 million.

  • Trinity Biotech's Common Equity rose 8550.04% to $4.3 million in Q2 2025 from the same period last year, while for Jun 2025 it was $4.3 million, marking a year-over-year increase of 8550.04%. This contributed to the annual value of $4.2 million for FY2024, which is 11247.46% up from last year.
  • Latest data reveals that Trinity Biotech reported Common Equity of $4.3 million as of Q2 2025, which was up 8550.04% from $4.2 million recorded in Q4 2024.
  • Over the past 5 years, Trinity Biotech's Common Equity peaked at $4.3 million during Q2 2025, and registered a low of $1.2 million during Q1 2021.
  • Moreover, its 5-year median value for Common Equity was $2.0 million (2023), whereas its average is $2.1 million.
  • Over the last 5 years, Trinity Biotech's Common Equity had its largest YoY gain of 27036.52% in 2021, and its largest YoY loss of 8284.54% in 2021.
  • Over the past 5 years, Trinity Biotech's Common Equity (Quarter) stood at $1.2 million in 2021, then soared by 61.83% to $2.0 million in 2022, then rose by 0.46% to $2.0 million in 2023, then soared by 112.47% to $4.2 million in 2024, then increased by 3.51% to $4.3 million in 2025.
  • Its Common Equity stands at $4.3 million for Q2 2025, versus $4.2 million for Q4 2024 and $2.4 million for Q3 2024.